Results 181 to 190 of about 273,933 (297)

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify noninvasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin, Leonardo Palazzo, Agnes B. Fogo, Mark Haas, David R. W. Jayne, Liz Lightstone, Brad H. Rovin, Surya V. Seshan, Augusto Vaglio, Ioannis Parodis, Ingeborg M. Bajema, for the Lupus Nephritis Classification Steering Committee   +11 more
wiley   +1 more source

A Case Report of Discoid Lupus Erythematosus Mimicking Skin Infection. [PDF]

Reports (MDPI)
Stoyanova Z, Hinkova E, Georgieva F, Popov H, Stoyanov G.   +4 more
europepmc   +1 more source

A Rare Case of Extensive Oral Involvement in Bullous Systemic Lupus Erythematosus: Diagnostic and Therapeutic Challenges. [PDF]

Int Med Case Rep J
Resmi T, Suwarsa O, Sufiawati I.
europepmc   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Surgical treatment of a giant aneurysm of the superior mesenteric artery in a patient with systemic lupus erythematosus. [PDF]

J Surg Case Rep
Mertens L, Bruder L, Carstens J, Haidar H, Greiner A.   +4 more
europepmc   +1 more source

Prothrombotic Activation of Platelet Pannexin‐1 Channels in Antiphospholipid Syndrome

Arthritis &Rheumatology, EarlyView.
Objective ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired ...
Bruna de Moraes Mazetto Fonseca, Somanathapura K. NaveenKumar, Srilakshmi Yalavarthi, Kavya Sugur, Thalia G. Newman, Claire K. Hoy, Cyrus Sarosh, Jordan K. Schaefer, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Fernanda A. Orsi, Michael Holinstat, Jason S. Knight   +13 more
wiley   +1 more source

Beyond Infection and Lupus Flare: MPO-ANCA Microscopic Polyangiitis Causing Diffuse Alveolar Hemorrhage in a Patient With Systemic Lupus Erythematosus. [PDF]

Clin Case Rep
Bocus A, Zaalouk TM, Chowdhury P, Nasim S.   +3 more
europepmc   +1 more source

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

Arthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

The risk factors of cerebral small vessel disease in patients with Systemic Lupus Erythematosus. [PDF]

BMC Rheumatol
Sun J, Wang H, Xu X, Liu L.
europepmc   +1 more source

Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden

Arthritis &Rheumatology, Accepted Article.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003‐2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003‐2022, and matched them to ...
Ngoc V. Nguyen, Anna Sandström, Annica Dominicus, Elisabet Svenungsson, Karin Hellgren, Julia F. Simard, Elizabeth V. Arkema   +6 more
wiley   +1 more source